Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -526.8%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $11M | $37M | $19579 | — | — | — | — | — |
| Enterprise Value | $11M | $37M | $497579 | — | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 0.11 | — | — | — | — | — |
| P/B Ratio | 10.16 | 66.67 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 2.72 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | -380.7% | -1697.3% | 30.7% | -1.7% |
| Operating Margin | — | — | -5421.3% | -9627.9% | -822.3% | -3120.2% | -561.4% | 319.1% |
| Net Profit Margin | — | — | -3951.9% | -9595.1% | -848.4% | -3069.8% | -561.4% | -327.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| ROE | -526.8% | -526.8% | — | — | — | -479.8% | — | — |
| ROA | -101.0% | -101.0% | -180.4% | -154.0% | -174.4% | -117.7% | -99.5% | -71.7% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | — | — | — | — | -757.4% | -166.9% | -121.6% | 92.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | — | — | — | 0.18 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.15 | — | — | — | -1.95 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -1.30 |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.49 | -7.49 | -17.69 | -507.96 | -67.08 | -881.00 | — | -87.54 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.10 | 0.10 | 0.19 | 0.15 | 0.89 | 1.53 | 5.71 | 3.84 |
| Quick Ratio | 0.10 | 0.10 | 0.19 | 0.15 | 0.89 | 1.53 | 5.71 | 3.84 |
| Cash Ratio | 0.01 | 0.01 | 0.15 | 0.06 | 0.67 | 1.47 | 5.54 | 3.75 |
| Asset Turnover | — | — | 0.04 | 0.04 | 0.17 | 0.06 | 0.13 | 0.22 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 644.24 | 263.28 | 365.18 | 30.42 | 30.51 | 23.39 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2.2B | $313267 | $311900 | $310400 | $309133 | $392200 | $387933 |
Immediate liquidity insolvency risk
Based on reported figures, the company's price-to-book ratio of 10.16 suggests that market participants are assigning value primarily to the DiversImmune platform's intellectual property rather than tangible assets, as the firm currently lacks the commercial revenue necessary to support traditional earnings-based valuation multiples like P/E or EV/EBITDA.
The elevated P/B ratio relative to peers like Xencor or MacroGenics appears to reflect a speculative premium on the potential of the tetravalent antibody architecture. Investors should monitor whether this valuation holds as the company's extreme liquidity constraints force potential dilutive capital raises that could reset the equity base.
As reported in financial statements, the current ratio of 0.74 in 2026Q1 highlights a severe inability to cover short-term obligations, a trend that has worsened significantly from previous periods and leaves the firm with virtually no margin for error in its clinical development timeline.
The quick ratio, which mirrors the current ratio at 0.74, confirms that the company possesses almost no liquid assets to offset its liabilities. This liquidity profile suggests that the firm is likely dependent on external financing or milestone payments to maintain its status as a going concern.
According to recent SEC filings, the company's asset turnover ratio of 0.03 in 2024Q4 underscores the lack of commercial activity, as the firm's capital base remains largely unproductive while it awaits clinical validation of its lead bispecific antibody candidates.
The minimal asset turnover is consistent with a pre-revenue biotechnology entity that has yet to transition from R&D to commercialization. This metric suggests that the company's current asset base is not generating meaningful economic output, which warrants further investigation into the efficiency of its R&D spending.
Based on the provided data, analysts frequently misapply net margin and ROE to this business model, failing to recognize that these metrics are distorted by non-recurring milestone payments and massive accumulated deficits that render traditional profitability analysis irrelevant for a clinical-stage firm.
Investors should instead focus on the cash burn rate and the probability of clinical success, as these are the true drivers of value. Relying on GAAP profitability ratios in this context obscures the reality that the company is currently a vehicle for high-risk R&D rather than a mature operating business.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABPWW stock.
Abpro Holdings Inc's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Abpro Holdings Inc's return on equity (ROE) is -526.8%. The historical average is -479.8%.
Based on historical data, Abpro Holdings Inc is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.